Linda W. Horton
Last active: 8/20/2015


I am the lab manager for the Richmond lab and, as such, wear a lot of "hats".  I manage the grant budgets, keep the lab compliant with the regulatory agencies (IRB, IACUC, etc.), maintain the lab, order supplies, assist with grant preparation, and so on.  In addition, I am working with Dr. Hawkins on several grant aims which involve animal models.  With a veterinary background, I help Dr. Richmond during grant preparation design valid in vivo experiments that yield statistically significant data with the minimum number of animals.  Finally, I serve as a "consumer advocate" on the Vanderbilt Research Advocate group and the Scientific Review Committee.  I have attended numerous conferences, again, in the role of advocate.  And I look at the grants which contain human subject components with an eye to the final goal.....alleviating cancer in the clinical setting.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia. Crowder SW, Horton LW, Lee SH, McClain CM, Hawkins OE, Palmer AM, Bae H, Richmond A, Sung HJ (2013) FASEB J 27(7): 2788-98
    › Primary publication · 23568779 (PubMed) · PMC3688746 (PubMed Central)
  2. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME (2011) Cancer Res 71(2): 603-13
    › Primary publication · 21123450 (PubMed) · PMC3140407 (PubMed Central)
  3. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Su Y, Amiri KI, Horton LW, Yu Y, Ayers GD, Koehler E, Kelley MC, Puzanov I, Richmond A, Sosman JA (2010) Clin Cancer Res 16(1): 348-57
    › Primary publication · 20028756 (PubMed) · PMC3205975 (PubMed Central)
  4. Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth. Horton LW, Yu Y, Zaja-Milatovic S, Strieter RM, Richmond A (2007) Cancer Res 67(20): 9791-9
    › Primary publication · 17942909 (PubMed) · PMC2668258 (PubMed Central)
  5. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A (2004) Cancer Res 64(14): 4912-8
    › Primary publication · 15256463 (PubMed)
  6. Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress. Du J, Luan J, Liu H, Daniel TO, Peiper S, Chen TS, Yu Y, Horton LW, Nanney LB, Strieter RM, Richmond A (2002) J Leukoc Biol 71(1): 141-53
    › Primary publication · 11781390 (PubMed) · PMC2665273 (PubMed Central)
  7. Visualization of eosinophil chemotactic factor in abomasal tissue of cattle by immunoperoxidase staining during Ostertagia ostertagi infection. Klesius PH, Snider TG, Horton LW, Crowder CH (1989) Vet Parasitol 31(1): 49-56
    › Primary publication · 2658300 (PubMed)
  8. Human tumor and normal tissue reactivity of the anti-(breast cancer) monoclonal antibody BA-Br-3 and its similarity to the anti-(epithelial membrane antigen) monoclonal antibody E29. Liao SK, Flahart RE, Kimbro B, Horton L, Oldham RK, Hilgers J, van der Gaag R (1990) Cancer Immunol Immunother 31(2): 65-75
    › Primary publication · 2182192 (PubMed)